ECC4703

DRUG4 trials

Sponsors

Eccogene

Conditions

Adult ObesityDyslipidaemiaMetabolic Dysfunction-associated SteatohepatitisNon-alcoholic Fatty Liver Disease (NAFLD)Non-alcoholic Steatohepatitis (NASH)Weight Management

Early Phase 1

FTIH of ECC4703 in Healthy Volunteers

CompletedNCT05552274

EccogeneNon-alcoholic Steatohepatitis (NASH)

Start: 2022-08-16End: 2023-10-26Updated: 2024-07-05

Phase 1

Study of ECC4703 With Sulfasalazine and Pitavastatin

RecruitingNCT07726368

EccogeneDyslipidaemia, Non-alcoholic Fatty Liver Disease (NAFLD)

Start: 2026-08-07End: 2026-12-01Target: 40Updated: 2026-09-10

Phase 2

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

RecruitingNCT07288138

EccogeneMetabolic Dysfunction-associated Steatohepatitis

Start: 2025-12-15End: 2027-09-29Target: 160Updated: 2026-09-09

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Active, not recruitingNCT07505303

EccogeneAdult Obesity, Weight Management

Start: 2026-03-23End: 2026-10-15Updated: 2026-06-25